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Open access under CC BY-NEarly reopening of the occluded artery is, thus, important in ischemic stroke, and it
has been calculated that 2 million neurons die every minute in an ischemic stroke if
no effective therapy is given; therefore, ‘‘Time is Brain.’’ In massive hemispheric
infarction and edema, surgical decompression lowers the risk of death or severe
disability defined as a modified Rankin Scale score greater than 4 in selected
patients. Themajority, around 80%-85% of all ischemic stroke victims, does not fulfill
the criteria for revascularization therapy, and also for these patients, there is no effec-
tive acute therapy. Also there is no established effective acute treatment of sponta-
neous intracerebral bleeding. Therefore, an effective therapy applicable to all
stroke victims is needed. The neuroprotective drug citicoline has been extensively
studied in clinical trials with volunteers and more than 11,000 patients with various
neurologic disorders, including acute ischemic stroke (AIS). The conclusion is that
citicoline is safe to use and may have a beneficial effect in AIS patients and most
beneficial in less severe stroke in older patients not treated with recombinant tissue
plasminogen activator. No other neuroprotective agent had any beneficial effect in
confirmative clinical trials or had any positive effect in the subgroup analysis. Citico-
line is the only drug that in a number of different clinical stroke trials continuously
had some neuroprotective benefit. Key Words: Stroke—neuroprotection—ischemic
stroke—thrombolysis—citicoline—ICTUS.
 2014 by National Stroke Association Open access under CC BY-NC-ND license.Treatment of Acute Stroke
The initial treatment in acute ischemic stroke (AIS) aims
at restoring brain perfusion rapidly with intravenous (iv)
thrombolysis using iv recombinant tissue plasminogen
activator (rt-PA), which is effective up to 4½ hours after
symptom onset.1 In the most severe strokes with a large
thrombus load and a proximal arterial occlusion, iv
thrombolysis is ineffective, but endovascular therapyf Neurology, University Hospital of Copen-
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C-ND license.did not improve functional outcome or mortality after2,3
or without4 iv t-PA compared with iv t-PA alone. Most
of the patients in these trials were endovascularly treated
with the Merci retriever, which is inferior to both the
Trevo5 and the Solitaire6 retrievers. There might be an
additional beneficial effect after iv thrombolysis by late
endovascular therapy up to 12 hours after symptom
onset, if the occluded artery is recanalized, when there
is a mismatch between a small diffusion-weighted mag-
netic resonance imaging (MRI) lesion and a large
perfusion-weighted MRI lesion.7 A small phase II study
demonstrated a beneficial effect of the addition of trans-
cranial Doppler to iv thrombolysis,8 and a large phase
III study (Clotbuster) is planned. In a small phase II study,
a new thrombolytic drug, Tenecteplase, was superior to
rt-PA in terms of reperfusion and clinical improvement.9
Early reopening of the occluded artery is, thus, important
in ischemic stroke, and it has been calculated that 2 million
neurons die every minute10 in an ischemic stroke if no
effective therapy is given; therefore, Time is Brain. Inascular Diseases, Vol. 23, No. 7 (August), 2014: pp 1764-1769
EFFECTS OF CITICOLINE 1765massive hemispheric infarction and edema, surgical
decompression lowers the risk of death or severe disability
defined as a modified Rankin Scale (mRS) score greater
than 4 in selected patients, whereas optimum criteria for
patient selection and for timing of decompressive surgery
are yet to be defined.11 In acute spontaneous intracranial
bleeding, intensive blood pressure lowering reduced he-
matoma growth more, the treatment delay was shorter af-
ter symptom onset,12 but the intensive blood pressure
lowering did not improve the clinical outcome,13,14 and
early surgical supratentorial hematoma evacuation may
be beneficial before the patient deteriorates,15 but there
was no benefit from early surgery when compared with
conservative treatment in the 2 largest randomized
controlled clinical trials.16,17
Thus, there is no established effective acute treatment
of spontaneous intracerebral bleeding. The majority,
around 80%-85% of all ischemic stroke victims, does not
fulfill the criteria for revascularization therapy, and also
for these patients, there is no effective acute therapy.
Therefore, an effective therapy applicable to all stroke vic-
tims is needed.Citicoline
Recent research suggests that drugs with the potential
to enhance endogenous brain plasticity and repair may
reduce acute brain damage and improve functional recov-
ery in animal models of stroke, even when they are
administered several hours after the ischemic event.18,19
One of these new drugs, which might combine
neurovascular protection and repair effect, is citicoline.
Citicoline is an exogenous form of cytidine-50-
diphosphocholine, which is an essential intermediate in
the generation of phosphatidylcholine and is essential
for the biosynthesis of membrane phospholipids, which
is degraded during brain ischemia to fatty acids and
free radicals.20 In addition, citicoline has been shown to
restore the activity of mitochondrial ATPase and mem-
brane Na1/K1ATPase, to inhibit activation of phospho-
lipase A2, and to accelerate reabsorption of cerebral
edema in various experimental models.21 Citicoline,
thus, acts at several levels of the ischemic cascade, and
a series of brain repair effects have been reported22 (Fig 1).
As shown by toxicologic tests, citicoline is a safe drug
with no significant systemic cholinergic effects and is a
well-tolerated drug. The pharmacologic characteristics
and the action mechanisms of citicoline suggest that
this drug may be indicated for the treatment of cerebral
vascular disease, head injury of varying severity, and
cognitive disorders of different causes. Citicoline has
been extensively studied in clinical trials with volun-
teers and more than 11,000 patients with various neuro-
logic disorders, including AIS. In all these studies,
citicoline had a similar safety profile compared with
placebo.20Phase II Studies of Citicoline
A phase II trial23 showed improved outcome in stroke
patients treated with either a 500 or 2000 mg/d dose of
citicoline. A phase III trial24 then randomized stroke pa-
tients in a 2:1 fashion to receive either 500 mg of citicoline
or placebo in an oral capsule per day for 6 weeks starting
within 24 hours of symptom onset. There were 267 pa-
tients in the citicoline-treated group and 127 patients in
the placebo group.
After 3 months, the citicoline-treated and placebo-
treated groups showed no significant differences on
selected assessments of functional outcome. There
were no significant side effects. Despite similar mean
baseline neurologic stroke scale scores, a higher percent-
age of patients treated with placebo had mild strokes. A
post hoc subgroup analysis suggested that patients with
more severe strokes (National Institutes of Health Stroke
Scale score .8) had better functional outcome with citi-
coline.
The effect of citicoline on infarct size on MRI in patients
with mild, moderate, and severe strokes were reported.25
Although this study also failed to show a significant
difference between treated and untreated groups, there
was a trend toward smaller infarct volumes in treated
patients.Phase III Studies of Citicoline
Another phase III trial 26 was then performed, involving
only moderate-to-large strokes. The drug showed no
adverse effects. Unfortunately, the company chose a novel
end point (National Institutes of Health Stroke Scale
[NIHSS] score improvement.7 points), and the trial result
was negative. If the company had instead used more con-
ventional end points (eg, NIHSS score 5 0 or 1, Rankin
score 5 0 or 1), the trial would have been positive.
In an individual patient-data, meta-analysis of 1371
pooled patients from 4 randomized, placebo-controlled,
double-blinded clinical trials. Citicoline (500-2000 mg
daily) was given to 789 patients with moderate-to-
severe ischemic stroke within 24 hours from stroke onset,
and results were compared with 583 patients on placebo.
The results were assessed using a generalized estimating
equation analysis to combine an NIHSS score of 1 or less,
mRS score of 1 or less, and a Barthel Index of 1 or less. Cit-
icoline significantly increased an essentially complete re-
covery at 3-month follow-up (odds ratio [OR] 1.33, 95%
confidence interval [CI] 1.10-1.62),27 confirmed in a later
meta-analysis.28
In The Lancet, Davalos et al29 report the results of the
International Citicoline Trial on Acute Stroke (ICTUS),
where the possible beneficial effect of citicoline for protec-
tion and repair of the brain from the ischemic injury was
tested in patients with AIS. The ICTUS fulfilled the
criteria for a therapy, which can be offered to all ischemic
Figure 1. Marked in red are the places
where citicoline has been demonstrated to
have a pharmacologic action in the ischemic
cascade. Note the effect on cell repair mech-
anisms. Abbreviations: ATP, adenosine
triphosphate; CBF, cerebral blood flow.
(Reproduced from Secades et al,21 2010
with permission from Viguera Editores
S.L.) (Color illustration of figure appears
online.)
K. OVERGAARD1766stroke victims. In the ICTUS, 2298 patients within 24 hours
from a moderate-to-severe ischemic stroke of the anterior
territory were randomly assigned to double-blinded
treatment with citicoline (2000 mg daily) or placebo for
6 weeks. Patients receiving citicoline were well balanced
with patients treated with placebo for baseline character-
istics and known risk factors for stroke. Despite the previ-
ous evidence, the ICTUS showed a neutral estimate of the
effect of treatment with citicoline. In the intention-to-treat
population, no significant difference was observed in the
primary outcome of recovery evaluated as an mRS score
0 to 2 (OR 5 .94, 95% CI .79-1.13 and OR 1.03, 95% CI
.86-1.25; P 5 .364) or as measured by a global test
combining the Barthel Index (95-100), mRS (score 0-1),
and the NIHSS (0-1) at 90 days. Secondary variables and
some subgroups defined in the protocol also gave neutral
results; there were no differences in the distribution of
mRS between the treatment groups assessed by shift anal-
ysis (OR for improvement over the 6 scores was 1.02 (95%
CI .88-1.19).Discussion of the Effects of Citicoline
There are a number of possible explanations for these
neutral results: The stroke care standard of patients
included in the ICTUS was so high that it was difficult
to demonstrate additional benefits with citicoline. All
patients in the ICTUS were treated in stroke units in
the university hospitals in Spain, Portugal, and Ger-
many. Treatment in stroke units is highly beneficial for
stroke patients and reduced the risk of death by 14% 1
year poststroke (OR .86, 95% CI .76-.98, P 5 .02) and
reduced the risk by 18% for death or living in nursinghome (OR .82, 95% CI .73-.92, P 5 .0006) and reduced
the risk by 18% for death or dependency (OR .82, 95 %
CI .73-.92, P 5 .001).30 These results were independent
of patient age, sex, and the severity of the stroke. Treat-
ment in a stroke unit was not associated with an
extended hospital stay. Analysis of prespecified sub-
groups in the ICTUS (Fig 2) demonstrated a possible
beneficial effect of citicoline compared with placebo in
patients not treated with rt-PA (P 5 .041). An unusual
large portion of 47% of the patients was treated with
rt-PA. The average percentage of use of rt-PA in stroke
patients in western countries is in the range of 6%-
22%.31 In the rest of the world, it is below 10%; rt-PA
may re-establish blood flow in the penumbra region,
and therefore, the benefit that citicoline could provide
is diluted demonstrating the difficulty of improving
the outcome on top of the effect of rt-PA, caused by a ceil-
ing effect of thrombolysis. Because of the severity of
most of the stroke patients included in the trial and
also the high percentage of rt-PA use, there was not
much penumbra area susceptible to be saved by means
of the citicoline treatment. Consequently, in the sub-
group without rt-PA, citicoline showed a positive effi-
cacy tendency. This is coherent with the fact that the
thrombolytic treatment seems to have interfered with
the potential beneficial effects of citicoline. The study
cannot be extrapolated to standard stroke clinical care
because of the high percentage of rt-PA use in this study.
Further analysis must be carried out on this subgroup to
better understand this positive efficacy trend. In conclu-
sion, the results of the ICTUS suggest that citicoline may
have a role to play in those patients with acute ischemic
stroke who are not treated with rt-PA (a majority in
Figure 2. Subgroup analysis of the ICTUS. Abbreviations: BI, Barthel Index; ICTUS, International Citicoline Trial on Acute Stroke; mRS, modified Rankin
Scale; NIHSS, National Institutes of Health Stroke Scale; rt-PA, recombinant tissue plasminogen activator. (Reproduced from Davalos et al,29 2012 with
permission from Elsevier).
EFFECTS OF CITICOLINE 1767standard clinical practice around the world), in whom
there is a penumbra area susceptible of being saved.
Analysis of other prespecified subgroups (Fig 2) also
demonstrated a possible beneficial effect of citicoline
comparedwith placebo in participants older than 70 years
(P 5 .001) and in patients with less-to-moderate stroke
severity (NIHSS score ,14, P 5 .021). This might reflect
a larger susceptibility of older brains to the detrimental
effect of ischemia, the known difficulty (also for throm-Figure 3. The major differences between
the ICTUS trial and the previous trials.
Abbreviations: ICTUS, International Citi-
coline Trial on Acute Stroke; NIHSS,
National Institutes of Health Stroke Scale;
rt-PA, recombinant tissue plasminogen
activator.bolysis) to improve the outcome of a severe stroke
because of extensive irreversible infarction. The explana-
tion for the difference between the results of the ICTUS
and the previous citicoline trials might also be the more
severe strokes. The patient’s NIHSS average value at in-
clusion was median 15, higher than a median of 14 in
the previous studies. The ICTUS, thus, included a high
percentage of severe stroke patients, with a smaller pen-
umbra area susceptible to being saved. Taking into
Figure 4. Forest plot for the updated tabu-
lated meta-analysis of clinical citicoline trials.
Odds ratio for good outcome was defined as a
modified Rankin Scale score of 0, 1, or 2. Ab-
breviations: CI, confidence interval; ICTUS,
International Citicoline Trial on Acute
Stroke. (Reproduced from Davalos et al,29
2012 with permission from Elsevier).
K. OVERGAARD1768account that citicoline acts in the penumbra area (showed
in previous studies to be a dose-dependent reduction in
infarct growth), the high percentage of patients with an
extensive infarcted area reduced the chances that citico-
line exerted a beneficial effect. These explanations and re-
sults are hypothesis generating rather than conclusive,
especially in a trial with an overall neutral result.32 The
major differences between the ICTUS and the previous
trials are displayed in Figure 3.
The results of the ICTUS, thus, seem valid and almost
doubles the available results of the effect of citicoline in
AIS. Davalos et al29 have set a high standard of quality
in the planning, conduction, and presentation of the
ICTUS. A new and updated meta-analysis of all the clin-
ical trials of citicoline demonstrated an overall signifi-
cant beneficial effect of citicoline, with an OR of 1.14
(95% CI 1.001-1.299) of obtaining a good clinical
outcome (mRS score 0-2) compared with placebo
(Fig 4). The safety profile of citicoline in the ICTUS
was as in the previous trials very good and comparable
with placebo, with no drug-related adverse events. As
such, the study does not reflect standard clinical prac-
tice, and thus, results cannot be extrapolated to real
stroke care around the world (not even to western coun-
tries, where the standard of care is higher than in the
other regions).
Conclusions
Citicoline is safe to use and may have a beneficial effect
in AIS patients, probably most beneficial in less severe
stroke (baseline NIHSS score ,14), patients older than
70 years, and patients not treated with rt-PA. No other
neuroprotective agent had any beneficial effect in confir-
mative clinical trials or had any positive effect in sub-
group analysis. Citicoline is the only drug that in a
number of different clinical stroke trials continuously
had some neuroprotective benefit.References
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